The novel ALK K1150dup mutation mediates resistance to frontline lorlatinib and retains sensitivity to gilteritinib
Mai Nagasaka(Nagoya City University), Luc Friboulet(Inserm)
Cited by 0
Related Papers
The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer
|Cancer Discovery|2014|842
Resistance to Selective FGFR Inhibitors in <i>FGFR-</i> Driven Urothelial Cancer
|Cancer Discovery|2023|69
Anti-Tumorigenic Activity of Chrysin from Oroxylum indicum via Non-Genotoxic p53 Activation through the ATM-Chk2 Pathway
|Molecules|2018|43
Poly(I:C) induces intense expression of c-IAP2 and cooperates with an IAP inhibitor in induction of apoptosis in cancer cells
|BMC Cancer|2010|24
Lysine-Specific Demethylase 1 (LSD1/KDM1A) Is a Novel Target Gene of c-Myc
|Biological and Pharmaceutical Bulletin|2019|18